Cognition and emotions in recurrent depressive disorders - The role of inflammation and the kynurenine pathway

Current Pharmaceutical Design

Volumn 22, Issue 8, 2016, Pages 955-962

  Talarowska, Monika ^a   Gałecki, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cognition; Depression; Emotion; Inflammation; Kynurenine; Social cognition

Indexed keywords

KYNURENINE;

AMYGDALOID NUCLEUS; ARTICLE; COGNITION; DECISION MAKING; DEPRESSION; EMOTION; EMOTIONAL DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; NEUROBIOLOGY; PRIORITY JOURNAL; PROBLEM SOLVING; RECURRENT DISEASE; REWARD; SOCIAL COGNITION; ANIMAL; COMPLICATION; DEPRESSIVE DISORDER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COGNITION; DEPRESSIVE DISORDER; EMOTIONS; HUMANS; INFLAMMATION; KYNURENINE; RECURRENCE; SIGNAL TRANSDUCTION;

EID: 84960110227     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151230110738     Document Type: Article

References (119)

1. Gray JR, Braver TS, Raichle ME. Integration of emotion and cognition in the lateral prefrontal cortex. Proc Natl Acad Sci USA 2002; 99(6): 4115-20.
2. Mitchell RL, Phillips LH. The psychological, neurochemical and functional neuroanatomical mediators of the effects of positive and negative mood on executive functions. Neuropsychologia 2007; 45: 617-29.
3. Ehret AM, Kowalsky J, Rief W, et al. Reducing symptoms of major depressive disorder through a systematic training of general emotion regulation skills: protocol of a randomized controlled trial. BMC Psychiatry 2014; 14: 20.
4. Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry 2014; 171: 829-43.
5. Nolen-Hoeksema S. Sex differences in unipolar depression: Evidence and theory. Psychol Bull 1987; 101: 259-82.
6. Aker M, Harmer C, Landrø NI. More rumination and less effective emotion regulation in previously depressed women with preserved executive functions. BMC Psychiatry 2014; 14: 334.
7. Weightman MJ, Air TM, Baune BT. A review of the role of social cognition in major depressive disorder. Front Psychiatry 2014; 5: 179.
8. Bartholomeusz CF, Whittle SL, Pilioussis E, et al. Relationship between amygdala volume and emotion recognition in adolescents at ultra-high risk for psychosis. Psychiatry Res 2014; 224(3): 159-67.
9. Horacek J, Mikolas P, Tintera J, et al. Sad mood induction has an opposite effect on amygdala response to emotional stimuli in euthymic patients with bipolar disorder and healthy controls. J Psychiatry Neurosci 2014; 39(6): 140044.
10. Hoertnagl CM, Hofer A. Social cognition in serious mental illness. Curr Opin Psychiatry 2014; 27(3): 197-202.
11. Helbig-Lang S, Rusch S, Lincoln TM. Emotion regulation difficulties in social anxiety disorder and their specific contributions to anxious responding. J Clin Psychol 2015; 71(3): 241-9.
12. McLaughlin KA, Nolen-Hoeksema S. Rumination as a transdiagnostic factor in depression and anxiety. Behav Res Ther 2011; 49(3): 186-93.
13. Rosenberg PB, Mielke MM, Xue QL, et al. Depressive symptoms predict incident cognitive impairment in cognitive healthy older women. Am J Ger Psych 2010; 18: 204-11.
14. Gualtieri T, Johnson L, Benedict K. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci 2006; 18(2): 217-26.
15. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry 2014; 75(1): 8-14.
16. Gaécki P, Talarowska M, Anderson G, et al. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression. Med Sci Monit 2015; 21: 1535-47.
17. Quinn ME, Joormann J. Control when it counts: change in executive control under stress predicts depression symptoms. Emotion 2015; [Epub ahead of print].
18. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets 2014; 13(10): 1804-18.
19. Grabe HJ, Wittfeld K, Hegenscheid K, et al. Alexithymia and brain gray matter volumes in a general population sample. Hum Brain Mapp 2014; 35(12): 5932-45.
20. Taylor GJ, Bagby RM, Parker JD. Disorders of affect regulation: alexithymia in medical and psychiatric illness. Cambridge: Cambridge University Press 1997.
21. Wiebking C, Northoff G. Neural activity during interoceptive awareness and its associations with alexithymia-An fMRI study in major depressive disorder and non-psychiatric controls. Front Psychol 2015; 6: 589.
22. Lopez-Duran NL, Kuhlman KR, George C, et al. Facial emotion expression recognition by children at familial risk for depression: high-risk boys are oversensitive to sadness. J Child Psychol Psychiatry 2013; 54: 565-74.
23. Surguladze SA, Young AW, Senior C, et al. Recognition accuracy and response bias to happy and sad facial expressions in patients with Major Depression. Neuropsychology 2004; 18: 212-18.
24. Yoon KL, Joormann J, Gotlib IH. Judging the intensity of facial expressions of emotion: depression-related biases in the processing of positive affect. J Abnorm Psychol 2009; 118: 223-8.
25. Schlipf S, Batra A, Walter G, et al. Judgment of emotional information expressed by prosody and semantics in patients with unipolar depression. Front Psychol 2013; 4: 461.
26. Joormann J, Gotlib IH. Emotion regulation in depression: relation to cognitive inhibition. Cogn Emot 2010; 24(2): 281-98.
27. Levens SM, Gotlib IH. Impaired selection of relevant positive information in depression. Depress Anxiety 2009; 26(5): 403-10.
28. Liu WH, Huang J, Wang LZ, et al. Facial perception bias in patients with major depression. Psychiatry Res 2012; 197(3): 217-20.
29. Day CV, Gatt JM, Etkin A, et al. Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. J Affect Disord 2015; 176: 141-50.
30. Münkler P, Rothkirch M, Dalati Y, et al. Biased recognition of facial affect in patients with major depressive disorder reflects clinical state. PLoS One 2015; 10(6): e0129863.
31. Levens SM, Gotlib IH. Updating emotional content in recovered depressed individuals: Evaluating deficits in emotion processing following a depressive episode. J Behav Ther Exp Psychiatry 2015; 48: 156-63.
32. Caruso DR, Mayer JD, Salovey P. Relation of an ability measure of emotional intelligence to personality. J Person Assess 2002; 79: 306-20.
33. Henderson SE, Vallejo AI, Ely BA, et al. The neural correlates of emotional face-processing in adolescent depression: a dimensional approach focusing on anhedonia and illness severity. Psychiatry Res 2014; 224(3): 234-41.
34. Briceño EM, Weisenbach SL, Rapport LJ, et al. Shifted inferior frontal laterality in women with major depressive disorder is related to emotion-processing deficits. Psychol Med 2013: 43(7): 1433-45.
35. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2007; 35: 192-216.
36. Neta M, Whalen PJ. Individual differences in neural activity during a facial expression vs. identity working memory task. Neuroimage 2011; 56(3): 1685-92.
37. Talarowska M, Orzechowska A, Florkowski A, et al. Emotional intelligence and working memory in depressive disorders. Curr Prob Psychiatry 2012; 13(2): 82-8.
38. Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: A psychometric analysis. Cogn Therapy Res 2003; 27: 247-59.
39. Joormann J, Gotlib IH. Updating the contents of working memory in depression: interference from irrelevant negative material. J Abnorm Psychol 2008; 117(1): 182-92.
40. Frühholz S, Grandjean D. Processing of emotional vocalizations in bilateral inferior frontal cortex. Neurosci Biobehav Rev 2013: 37(10 Pt 2): 2847-55.
41. Rosenblau G, Sterzer P, Stoy M, et al. Functional neuroanatomy of emotion processing in major depressive disorder is altered after successful antidepressant therapy. J Psychopharmacol 2012; 26(11): 1424-33.
42. Dara C, Bang J, Gottesman RF, et al. Right hemisphere dysfunction is better predicted by emotional prosody impairments as compared to neglect. J Neurol Transl Neurosci 2014: 2(1): 1037.
43. Talarowska M, Zajćzkowska M, Gaécki P. Emotional and language prosody and working memory in patients with depression. Pol Merkur Lekarski 2015; 38(227): 269-72.
44. Hallam GP, Webb TL, Sheeran P, et al. The neural correlates of emotion regulation by implementation intentions. PLoS One 2015; 10(3): e0119500.
45. Cusi AM, Nazarov A, Holshausen K, et al. Systematic review of the neural basis of social cognition in patients with mood disorders. J Psychiatry Neurosci 2012; 37: 154-69.
46. Kerestes R, Davey CG, Stephanou K, et al. Functional brain imaging studies of youth depression: a systematic review. Neuroimage Clin 2013; 4: 209-31.
47. Schmaal L, Veltman DJ, van Erp TG, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2015; Jun 30. doi: 10. 1038/mp. 2015. 69. [Epub ahead of print].
48. Graham J, Salimi-Khorshidi G, Hagan C, et al. Meta-analytic evidence for neuroimaging models of depression: state or trait? J Affect Disord 2013; 151: 423-31.
49. Yang R, Zhang H, Wu X, et al. Hypothalamus-anchored resting brain network changes before and after sertraline treatment in major depression. Biomed Res Int 2014; 2014: 915026.
50. Fu CH, Costafreda SG, Sankar A, et al. Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine. BMC Psychiatry 2015; 15: 82.
51. Grieve SM, Korgaonkar MS, Koslow SH, Gordon E, Williams LM. Widespread reductions in gray matter volume in depression. Neuroimage Clin 2013; 3: 332-9.
52. Du M, Liu J, Chen Z, et al. Brain grey matter volume alterations in late-life depression. J Psychiatry Neurosci 2014; 39(6): 397-406.
53. Bijanki KR, Hodis B, Brumm MC, et al. Hippocampal and left subcallosal anterior cingulate atrophy in psychotic depression. PLoS One 2014; 9(10): e110770.
54. Bernasconi R, Smieskova R, Schmidt A, et al. Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. Neuroimage Clin 2015; 8: 230-7.
55. Ma N, Li L, Shu N, et al. White matter abnormalities in firstepisode, treatment-naive young adults with major depressive disorder. Am J Psychiatry 2007; 164: 823-6.
56. Ho TC, Connolly CG, Henje Blom E, et al. Emotion-dependent functional connectivity of the default mode network in adolescent depression. Biol Psychiatry 2015; 78(9): 635-46.
57. Pan LA, Ramos L, Segreti A, et al. Right superior temporal gyrus volume in adolescents with a history of suicide attempt. Br J Psychiatry 2015; 206(4): 339-40.
58. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbiccortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-82.
59. Delaveau P, Jabourian M, Lemogne C, et al. Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord 2011; 130(1-2): 66-74.
60. Price JL. Comparative aspects of amygdala connectivity. Ann N Y Acad Sci 2003; 985: 50-8.
61. Young KD, Zotev V, Phillips R, et al. Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder. PLoS One 2014; 9(2): e88785.
62. Suslow T, Kugel H, Reber H, et al. Automatic brain response to facial emotion as a function of implicitly and explicitly measured extraversion. Neuroscience 2010; 167(1): 111-23.
63. Chen YT, Huang MW, Hung IC, et al. Right and left amygdalae activation in patients with major depression receiving antidepressant treatment, as revealed by fMRI. Behav Brain Funct 2014; 10(1): 36.
64. Briceño EM, Rapport LJ, Kassel MT, et al. Age and gender modulate the neural circuitry supporting facial emotion processing in adults with major depressive disorder. Am J Geriatr Psychiatry 2015; 23(3): 304-13.
65. Di Simplicio M, Norbury R, Reinecke A, et al. Paradoxical effects of short-term antidepressant treatment in fMRI emotional processing models in volunteers with high neuroticism. Psychol Med 2014; 44(2): 241-52.
66. Fisher PM, Meltzer CC, Price JC, et al. Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling. Cereb Cortex 2009; 19: 2499-507.
67. Surguladze SA, Radua J, El-Hage W, et al. Interaction of catechol O-methyltransferase and serotonin transporter genes modulates effective connectivity in a facial emotion-processing circuitry. Transl Psychiatry 2012; 2: e70.
68. Outhred T, Hawkshead BE, Wager TD, et al. Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. Neurosci Biobehav Rev 2013; 37(8): 1786-800.
69. McRae K, Rekshan W, Williams LM, et al. Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report. J Affect Disord 2014; 159: 127-32.
70. Shiroma PR, Thuras P, Johns B, et al. Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. Int J Geriatr Psychiatry 2014; 29(11): 1132-9.
71. Malykhin NV, Coupland NJ. Hippocampal neuroplasticity in major depressive disorder. Neuroscience 2015; 309: 200-13.
72. Patten SB, Wang JL, Williams JV, et al. Predictors of the longitudinal course of major depression in a Canadian population sample. Can J Psychiatry 2010; 55(10): 669-76.
73. Whittle S, Yap MB, Sheeber L, et al. Hippocampal volume and sensitivity to maternal aggressive behavior: A prospective study of adolescent depressive symptoms. Dev Psychopathol 2011; 23(1): 115-29.
74. Vreeburg SA, Hoogendijk WJ, van Pelt J, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: Results from a large cohort study. Arch Gen Psychiatry 2009; 66(6): 617-26.
75. Hansson PB, Murison R, Lund A, et al. Cognitive functioning and cortisol profiles in first episode major depression. Scand J Psychol 2015; 56(4): 379-83.
76. Porter RJ, Gallagher P. Abnormalities of the HPA axis in affective disorders: Clinical subtypes and potential treatments. Acta Neuropsychiatr 2006; 18: 193-209.
77. Milne AM, MacQueen GM, Hall GB. Abnormal hippocampal activation in patients with extensive history of major depression: an fMRI study. J Psychiatry Neurosci 2012; 37(1): 28-36.
78. Egeland J, Lund A, Landrø NI, et al. Cortisol level predicts executive and memory function in depression, symptom level predicts psychomotor speed. Acta Psychiatr Scand 2005; 112(6): 434-41.
79. Krause-Utz A, Oei NY, Niedtfeld I, et al. Influence of emotional distraction on working memory performance in borderline personality disorder. Psychol Med 2012; 42(12): 2181-92.
80. LeMoult J, Joormann J. Depressive rumination alters cortisol decline in Major Depressive Disorder. Biol Psychol 2014; 100: 50-5.
81. Stewart JG, Mazurka R, Bond L, et al. Rumination and impaired cortisol recovery following a social stressor in adolescent depression. J Abnorm Child Psychol 2013; 41(7): 1015-26.
82. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci 2006; 8(4): 367-81.
83. Grant MM, White D, Hadley J, et al. Early life trauma and directional brain connectivity within major depression. Hum Brain Mapp 2014; 35(9): 4815-26.
84. Maes M, Kubera M, Mihaylova I, et al. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J Affect Disord 2013; 149(1-3): 23-9.
85. Réus GZ, Jansen K, Titus S, et al. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. J Psychiatr Res 2015; 68: 316-28.
86. Halaris A, Myint AM, Savant V, et al. Does escitalopram reduce neurotoxicity in major depression? J Psychiatr Res 2015; 66-67: 118-26.
87. Talarowska M, Szemraj J, Berk M, et al. Oxidant/antioxidant imbalance is an inherent feature of depression. BMC Psychiatry 2015; 15: 71.
88. Dantzer R, O'Connor JC, Lawson MA, et al. Inflammation associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426-436.
89. Oxenkrug G. Interferon-gamma-inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis 2011; 2(6): 474-86.
90. Bradley KA, Case JA, Khan O, et al. The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatr Res 2015; 227(2-3): 206-12.
91. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-β-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 2014; 42: 222-31.
92. Myint AM, Kim YK. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 304-13.
93. Salazar A, Gonzalez-Rivera BL, Redus L, et al. Indoleamine 2, 3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav 2012; 62: 202-9.
94. Quak J, Doornbos B, Roest AM, et al. Does tryptophan degradation along the kynurenine pathway mediate the association between proinflammatory immune activity and depressive symptoms? Psychoneuroendocrinology 2014; 45: 202-10.
95. Dahl J, Andreassen OA, Verkerk R, et al. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers. Psychoneuroendocrinology 2015; 56: 12-22.
96. Müller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub 2013; 25(3): 292-8.
97. Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J Neuroinflamm 2014; 11: 151.
98. Jayawickrama GS, Sadig RR, Sun G, et al. Kynurenine aminotransferases and the prospects of inhibitors for the treatment of schizophrenia. Curr Med Chem 2015; 22(24): 2902-18.
99. Hüfner K, Oberguggenberger A, Kohl C, et al. Levels in neurotransmitter precursor amino acids correlate with mental health in patients with breast cancer. Psychoneuroendocrinology 2015; 60: 28-38.
100. Nikkheslat N, Zunszain PA, Horowitz MA, et al. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav Immun 2015; 48: 8-18.
101. Martinez P, Tsai AC, Muzoora C, et al. Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ARTtreated HIV-infected Ugandans. J Acquir Immune Defic Syndr 2014; 65(4): 456-62.
102. Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-Daspartate receptor in depression and suicidality. Brain Behav Immun 2015; 43: 110-7.
103. Kim H, Chen L, Lim G, et al. Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012; 122(8): 2940-54.
104. Petrova NN, Dorofeykova MV. Mechanisms of neurocognitive deficit development in schizophrenia and current treatment approaches. Zh Nevrol Psikhiatr Im S S Korsakova 2014; 114(11): 116-23.
105. Turski WA, Nakamura M, Todd WP, et al. Identification and quantification of kynurenic acid in human brain tissue. Brain Res 1988; 454 (1-2): 164-9.
106. Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol 2015; 40: 134-41.
107. Schwarz MJ, Guillemin GJ, Teipel SJ, et al. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur Arch Psychiatry Clin Neurosci 2013; 263(4): 345-52.
108. Yu D, Tao BB, Yang YY, et al. The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. J Alzheimers Dis 2015; 43(1): 291-302.
109. Gold AB, Herrmann N, Swardfager W, et al. The relationship between indoleamine 2, 3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 2011; 8: 17.
110. Savitz J, Drevets WC, Smith CM, et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015; 40(2): 463-71.
111. Heisler JM, O'Connor JC. Indoleamine 2, 3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav Immun 2015; 50: 115-24.
112. Pocivavsek A, Thomas MA, Elmer GI, et al. Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl) 2014; 231(14): 2799-809.
113. Akagbosu CO, Evans GC, Gulick D, et al. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr Bull 2012; 38(4): 769-78.
114. Alexander KS, Pocivavsek A, Wu HQ, et al. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 2013; 238: 19-28.
115. Kozak R, Campbell BM, Strick CA, et al. Reduction of brain kynurenic acid improves cognitive function. J Neurosci 2014; 34(32): 10592-602.
116. Guloksuz S, Arts B, Walter S, et al. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway. Brain Behav Immun 2015; 48: 48-52.
117. Savitz J, Drevets WC, Wurfel BE, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun 2015; 46: 55-9.
118. Frodl T, Szyf M, Carballedo A, et al. DNA methylation of the serotonin transporter gene (SLC6A4) is associated with brain function involved in processing emotional stimuli. J Psychiatry Neurosci 2015; 40(2): 140180.
119. Marroquín B, Nolen-Hoeksema S. Event prediction and affective forecasting in depressive cognition: using emotion as information about the future. J Soc Clin Psychol 2015; 34(2): 117-34.